Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−0.1 ILS
−223.55 M ILS
17.70 M ILS
1.22 B
About BIOLINE RX
Sector
CEO
Philip Adam Serlin
Headquarters
Modi'in
Website
Founded
2003
ISIN
IL0011015182
FIGI
BBG000D3FWW6
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of BLRX is 6.5 ILA — it hasn't changed in the past 24 hours. Watch BIOLINE RX stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on TASE exchange BIOLINE RX stocks are traded under the ticker BLRX.
BLRX stock has risen by 13.79% compared to the previous week, the month change is a −21.43% fall, over the last year BIOLINE RX has showed a −82.89% decrease.
We've gathered analysts' opinions on BIOLINE RX future price: according to them, BLRX price has a max estimate of 218.36 ILA and a min estimate of 48.52 ILA. Watch BLRX chart and read a more detailed BIOLINE RX stock forecast: see what analysts think of BIOLINE RX and suggest that you do with its stocks.
BLRX reached its all-time high on Oct 19, 2009 with the price of 5,898.0 ILA, and its all-time low was 5.3 ILA and was reached on Dec 19, 2024. View more price dynamics on BLRX chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
BLRX stock is 9.52% volatile and has beta coefficient of 1.24. Track BIOLINE RX stock price on the chart and check out the list of the most volatile stocks — is BIOLINE RX there?
Today BIOLINE RX has the market capitalization of 88.22 M, it has increased by 15.52% over the last week.
Yes, you can track BIOLINE RX financials in yearly and quarterly reports right on TradingView.
BIOLINE RX is going to release the next earnings report on Mar 26, 2025. Keep track of upcoming events with our Earnings Calendar.
BIOLINE RX revenue for the last quarter amounts to 18.45 M ILA, despite the estimated figure of 19.74 M ILA. In the next quarter, revenue is expected to reach 28.49 M ILA.
BLRX net income for the last quarter is −21.62 M ILS, while the quarter before that showed 1.80 M ILS of net income which accounts for −1.30 K% change. Track more BIOLINE RX financial stats to get the full picture.
No, BLRX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 30, 2024, the company has 38.00 employees. See our rating of the largest employees — is BIOLINE RX on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. BIOLINE RX EBITDA is −93.63 M ILS, and current EBITDA margin is −866.81%. See more stats in BIOLINE RX financial statements.
Like other stocks, BLRX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade BIOLINE RX stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So BIOLINE RX technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating BIOLINE RX stock shows the strong sell signal. See more of BIOLINE RX technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.